Opinion

Video

Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway

Author(s):

Adam M. Brufsky, MD, PhD,Erika P. Hamilton, MD

Key opinion leaders explore the mechanisms of resistance that can develop after endocrine therapy and CDK4/6 inhibitor treatment in HR+/HER2- locally advanced or metastatic breast cancer, emphasizing the uncertain etiology of resistance and current hypotheses, while also examining biomarkers that may predict resistance to CDK4/6 inhibitors and endocrine therapy.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
View More
Related Content
Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.
April 26th 2025

The OncFive: Top Oncology Articles for the Week of 4/20

Yvonne Mowery, MD, PhD, physician scientist, associate professor, radiation oncology, University of Pittsburgh Medical Center Hillman Cancer Center
January 7th 2025

Pembrolizumab Plus Preoperative Radiotherapy and Surgery Improves DFS in Soft-Tissue Sarcoma: With Yvonne Mowery, MD, PhD

Reshma Mahtani, DO
April 22nd 2025

Female Leadership and Representation in Oncology Is an Immense ‘Honor and Responsibility’

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

Image Credit: © Sebastian Kaulitzki – stock.adobe.com
April 21st 2025

Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1–Positive mTNBC

Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
April 21st 2025

T-DXd/Pertuzumab Yields PFS Benefit vs THP in HER2+ Metastatic Breast Cancer